Share on StockTwits

Bioclinica’s (NASDAQ:BIOC) lock-up period is set to end on Monday, August 4th. Bioclinica had issued 1,900,000 shares in its initial public offering on February 5th, Stock Ratings Network reports. The total size of the offering was $19,000,000 based on an initial share price of $10.00. After the expiration of Bioclinica’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Separately, analysts at Aegis initiated coverage on shares of Bioclinica in a research note on Tuesday, June 3rd. They set a “buy” rating and a $16.00 price target on the stock.

Shares of Bioclinica (NASDAQ:BIOC) traded down 2.98% during mid-day trading on Friday, hitting $4.88. The stock had a trading volume of 16,693 shares. Bioclinica has a 52-week low of $4.16 and a 52-week high of $10.02. The stock has a 50-day moving average of $5.83 and a 200-day moving average of $6.35. The company’s market cap is $21.7 million.

BioClinica, Inc, formerly Bio-Imaging Technologies, Inc, provides integrated clinical research services, including imaging core lab and eClinical technologies and services to pharmaceutical, biotechnology, and medical device companies, and other organizations, such as contract research organizations (NASDAQ:BIOC), engaged in global clinical studies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.